Ibrutinib for B cell malignancies.
Exp Hematol Oncol
; 3(1): 4, 2014 Jan 28.
Article
in En
| MEDLINE
| ID: mdl-24472371
ABSTRACT
Research over the role of Bruton's agammaglobulinemia tyrosine kinase (BTK) in B-lymphocyte development, differentiation, signaling and survival has led to better understanding of the pathogenesis of B-cell malignancies. Down-regulation of BTK activity is an attractive novel strategy for treating patients with B-cell malignancies. Ibrutinib (PCI-32765), a potent inhibitor of BTK induces impressive responses in B-cell malignancies through irreversible bond with cysteine-481 in the active site of BTK (TH/SH1 domain) and inhibits BTK phosphorylation on Tyr223. This review discussed in details the role of BTK in B-cell signaling, molecular interactions between B cell lymphoma/leukemia cells and their microenvironment. Clinical trials of the novel BTK inhibitor, ibrutinib (PCI-32765), in B cell malignancies were summarized.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
Exp Hematol Oncol
Year:
2014
Document type:
Article